Oncolytics Biotech To Present Trail-In-Progress Abstract, E-Poster For Its REO 033 Trial At European Society For Medical Oncology
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the Company is presenting a trial-in-progress
Oncolytics Biotech is showing early results from a cancer treatment study. When a company shares research progress like this, it signals they are moving forward with their work.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.